Association of Symptoms and Collaborative Care Intervention (TĀCcare) with Systemic Inflammation Biomarkers in End-Stage Kidney Disease

What is it about?

Elevations in pro-inflammatory biomarkers have been linked to poor health outcomes including higher symptom burden, disease progression, and mortality in patients with kidney disease. To our knowledge, this is the first study to examine the impact of a collaborative care intervention for pain, fatigue, and depression on inflammation biomarkers in a large randomized clinical trial (TĀCcare) of patients with ESKD. While all patients had decreases in anti-inflammatory cytokines over time, those randomized to our intervention reported significant decreases in pro-inflammatory biomarkers, while those in our control had a significant increase from baseline to 3 months. These results provide evidence for the potential of symptom improvement to attenuate inflammatory burden in patients with ESKD

Featured Image